Follistatin 344

Follistatin 344 (FST-344) is one of the naturally occurring isoforms of follistatin, a secreted protein that binds and neutralizes members of the TGF-beta superfamily — most notably myostatin and activin. Because myostatin acts as a natural "brake" on muscle growth, follistatin has attracted research interest as a way to release that brake.

It is important to distinguish follistatin from myostatin itself: follistatin is the inhibitor, whereas myostatin is the growth-limiting signal being inhibited. FST-344 is also distinct from the FST-315 isoform, and these differences in structure and binding behavior are central to how researchers interpret the molecule.

The proposed mechanism, based largely on preclinical research, centers on follistatin's ability to sequester myostatin and related ligands so they cannot activate their receptors. High-level themes include:

• Binding and inhibiting myostatin, removing a natural limit on muscle growth
• Binding activin, another TGF-beta family member with broad signaling roles
• Downstream shifts in pathways associated with muscle protein balance

Whether and how these mechanisms translate into durable, clinically meaningful muscle or functional changes in humans remains an area of active investigation rather than an established outcome.

FST-344 and FST-315 arise from alternative processing of the same gene and differ at their C-terminal region, which affects properties such as tissue binding and circulation. Research discussions often note these isoform differences because they can influence how the protein distributes and behaves, and conflating the two can lead to inaccurate claims.

Follistatin 344 is not an FDA-approved therapy. It has been explored preclinically — including through recombinant protein and gene-therapy approaches — in the context of muscle-wasting conditions and muscular dystrophies, where reducing myostatin activity is a plausible target.

Much of the online interest reflects extrapolation from these muscle-growth mechanisms to athletic or cosmetic goals. That extrapolation is not supported by controlled human efficacy or safety trials, and any consideration of follistatin should be grounded in local regulations and the distinction between research and validated treatment.

Follistatin is named by name on the WADA Prohibited List, not swept in by a catch-all. Sub-section S4.3, "Agents preventing activin receptor IIB activation," lists myostatin inhibitors and gives "myostatin-binding proteins (e.g. follistatin, myostatin propeptide)" as an explicit example, alongside decoy activin receptors such as ACE-031, anti-ActRIIB antibodies such as bimagrumab, and myostatin-neutralizing antibodies such as apitegromab, domagrozumab, landogrozumab and stamulumab. S4.3 substances are non-Specified: four-year default sanction, in and out of competition.

Two consequences are worth being precise about.

• The listing is about the binding activity, not the isoform. FS-344 is the gene transcript that yields FST-315; the list does not distinguish follistatin variants, gene-therapy constructs, or "follistatin peptide" fragments sold under research labels. Anything acting as a myostatin-binding protein is in scope.

• Gray-market identity is unreliable in this exact class. When 14 products sold as ACE-031 — the other prominent myostatin-pathway gray-market item — were analysed, none contained the advertised ActRIIB-Fc fusion protein, and the products carried numerous additional proteins (Reichel et al., Drug Test Anal 2025). Buying a labelled myostatin inhibitor is not the same as receiving one — and an unidentified protein injection is still an anti-doping and a safety exposure.

Note also that follistatin is an endogenous protein, so a positive finding requires distinguishing administered material from natural production; the prohibition therefore does most of its practical work through possession and investigation cases rather than routine screening.

Because follistatin binds activin and other TGF-beta family members that have wide-ranging roles, a recurring theoretical concern is off-target effects on tissues and processes beyond muscle. Gene-therapy delivery approaches raise their own distinct safety considerations.

As with other experimental biologics, careful attention to product sourcing, regulatory guidance, and individual risk factors is important. High-level summaries cannot substitute for rigorous safety evaluation.

Follistatin 344 is a protein, and its pharmacology is shaped by factors such as isoform identity, binding affinity for myostatin and activin, tissue distribution, and clearance. Delivery strategies studied in research range from recombinant protein to gene-therapy vectors, each with very different exposure profiles.

This information summarizes conceptual pharmacology and does not constitute medical advice or a usage recommendation.

"Follistatin" in the research literature refers to at least three physically different things, and they are not interchangeable:

• Recombinant follistatin protein. A secreted, disulfide-rich glycoprotein produced in mammalian cell culture. The two main forms behave very differently in tissue: FS-288 binds heparan sulfate and sticks to cell surfaces, while FS-315 binds neither and is simply secreted into the surrounding medium — so the isoform determines whether follistatin acts locally or circulates (Sugino et al., J Biol Chem 1993).

• The AAV gene-therapy construct. Every published human follistatin study used AAV1.CMV.FS344 — a virus carrying the FS344 transcript, injected directly into the quadriceps muscles under imaging guidance, so that the muscle itself manufactures follistatin continuously (Mendell et al., Mol Ther 2015). The investigators chose FS344 specifically "to avoid potential binding to off target sites."

• Vials labelled "Follistatin 344." A lyophilized powder, usually 1 mg, of unverified identity. Independent analysis of the closest comparable gray-market item — products sold as ACE-031 — found none contained the advertised protein, and all carried numerous additional proteins (Reichel et al., Drug Test Anal 2025).

Because follistatin is a folded, disulfide-rich, glycosylated protein rather than a short synthetic chain, the manufacturing bar is far higher than for a typical research peptide, and identity cannot be inferred from a label.

Research on follistatin has examined myostatin and activin inhibition and downstream effects on muscle in cell and animal models, along with gene-therapy strategies aimed at muscle-wasting conditions. These studies have generated genuine scientific interest, but the human evidence base for the goals commonly discussed online remains limited.

Because much of the data are preclinical and delivery is a major unresolved challenge, claims about follistatin should be interpreted cautiously. High-level overviews are not a substitute for critical appraisal of primary data.

For deeper dives on this compound, see:

• Follistatin 344 benefits and areas of interest
• Follistatin 344 side effects and safety context
• Follistatin 344 dosing concepts (educational)
• Follistatin 344 research and evidence overview

What does the "344" actually mean? It is a count of amino acids in a precursor, not a product name. When the human follistatin gene was first sequenced, three of eight cDNA clones predicted a 344-residue precursor and the other five predicted a 317-residue precursor, the difference arising from alternative splicing (Shimasaki et al., PNAS 1988). Each precursor carries a 29-residue signal sequence that is cut off during secretion, so FS-344 becomes the mature 315-residue protein and FS-317 becomes the 288-residue one. "Follistatin 344" therefore names a transcript that no longer exists by the time the protein is doing anything.

What human evidence exists for follistatin? Two small gene-therapy trials, both from the same centre, both delivering the FS344 transcript by AAV1 injected straight into the quadriceps. In six men with Becker muscular dystrophy, four improved on the six-minute walk test by 29–125 metres and two did not (Mendell et al., Mol Ther 2015). In six people with sporadic inclusion body myositis, annualised walking distance improved by +56.0 m/year against −25.8 m/year in eight matched untreated comparators (p = 0.01) (Mendell et al., Mol Ther 2017). Twelve treated people in total, no placebo arm, no replication elsewhere.

Does that gene-therapy result apply to injecting follistatin? No, and this is the central confusion on the topic. Those trials did not administer follistatin at all — they administered a virus carrying the gene, so that treated muscle would make the protein locally and continuously for months or years. Injecting a protein subcutaneously produces a brief systemic exposure, which is a different intervention with different pharmacology and its own unstudied safety profile. No trial has ever given people recombinant follistatin protein.

Is follistatin the same thing as myostatin? They are opposites. Myostatin (GDF-8) is the signal that restrains muscle growth; follistatin is one of the proteins that binds and neutralises it. Follistatin also binds activin and other TGF-beta family ligands, which is the source of the recurring concern about effects outside muscle — the same lack of selectivity that ended the ACE-031 program through vascular side effects.

Is follistatin approved anywhere? No. There is no approved follistatin product, gene therapy or protein, in any major jurisdiction. The broader myostatin-blocking field has yet to produce an approved drug for muscle mass; the most advanced candidate, the antibody apitegromab, has an FDA action date of 30 September 2026 and was not approved as of this page's update (Cure SMA).

Why is follistatin banned in sport if it is a natural protein? Because the 2026 Prohibited List bans it by activity, not by origin. S4.3 names "myostatin-binding proteins (e.g. follistatin, myostatin propeptide)" as prohibited at all times, and the sub-section also covers "agents reducing or ablating myostatin expression" — wording broad enough to reach gene-therapy constructs (WADA Prohibited List). S4.3 substances are non-Specified, carrying a four-year default sanction.